The development of immunotherapies faces major challenges such as the inability to predict treatment efficacy and patient response; the need for additional biomarkers; the development of resistance to immunotherapies; the lack of translational tools; the optimization of clinical study designs thanks to precision medicine.
Therefore, expected innovations should include more targeted treatments, the development of personalized biomarker profiles, drug combination therapies to improve efficacy and reduce toxicity.
Open innovation can be tapped and used to open up the necessary and expected innovations thanks to the cross-linking of knowledge and know-how from both Pharma or Biotech industries and external innovation partners.
Within this framework, Oncodesign has built up a network of key partners (Cynbiose, CERB & Aepodia & PharmaLex) convinced that these complex developments require the use of a collaborative and creative research organizations network permitting Pharma or Biotech companies to manage innovative projects from discovery stage to clinical trials. We bring together technological platforms, skills and knowledge, ability to set up an appropriate project governance structure within a comprehensive view of the immunotherapy development process.
The aim of this symposium is to address the current trends in Immunotherapies discovery & development from an academic, industrial and regulatory affairs point of view. It will also allow to depict how collaborative research organizations can bring their added values within this context.